Efficacy and safety of daily drug regimens containing high-dose versus standard-dose rifampicin for treating pulmonary tuberculosis: Systematic review and meta-analysis
Ashutosh N. Aggarwal, Ritesh Agarwal, Sahajal Dhooria, Perumal K. Bhavani, Kuruswamy T. Prasad, Inderpaul S. Sehgal, Valliappan Muthu · 2026
Read Efficacy and safety of daily drug regimens containing high-dose versus standard-dose rifampicin for treating pulmonary tuberculosis: Systematic review and meta-analysis by Ashutosh N. Aggarwal, Ritesh Agarwal, Sahajal Dhooria, Perumal K. Bhavani, Kuruswamy T. Prasad, Inderpaul S. Sehgal, Valliappan Muthu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13186494.txt.
Description
Ashutosh Aggarwal and six co-authors weigh higher doses of a key TB drug in this twenty twenty-six review. The standard dose of rifampicin sits at the low end of the range where more drug gives more effect. The team asked whether raising the daily dose cures more people or causes more harm.
They searched the literature for trials that compared standard and high daily doses for lung TB. Main checks were whether germ tests turned negative by set points in treatment, and whether severe liver harm rose. Other checks covered death, failure, and return of disease. The pooled answer can guide dosing rules for a disease still treated with old drugs.
Catalog record
| CREATOR | Ashutosh N. Aggarwal, Ritesh Agarwal, Sahajal Dhooria, Perumal K. Bhavani, Kuruswamy T. Prasad, Inderpaul S. Sehgal, Valliappan Muthu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |